摘要
目的:分析血清尿激酶型纤溶酶原激活物(uPA)水平在卵巢上皮性癌化疗患者中的变化及临床意义。方法:以笔者所在医院2018年6月-2019年6月收治的50例卵巢上皮性癌患者为研究对象,均予以TP化疗方案,分别在化疗前后检测其血清uPA水平;比较不同类型患者化疗前后血清uPA水平。结果:不同病理类型、病理分期、分化程度、淋巴结转移患者化疗后血清uPA水平均低于化疗前,差异均有统计学意义(P<0.05);非浆液性癌、Ⅰ或Ⅱ期、低中分化、淋巴结无转移患者化疗前后血清uPA水平均低于浆液性癌、Ⅲ或Ⅳ期、高分化、淋巴结转移患者,差异均有统计学意义(P<0.05)。结论:经化疗后,卵巢上皮性患者血清uPA水平有所下降。血清uPA水平变化在卵巢上皮性癌化疗患者中的实践,可为患者预后评估提供可靠依据。
Objective:To analyze the changes and clinical significance of serum urokinase-type plasminogen activator (uPA) levels in chemotherapy patients with ovarian epithelial cancer.Method:A total of 50 patients with epithelial ovarian cancer admitted to the author’s hospital from June 2018 to June 2019 were studied,they were all given TP chemotherapy regimen,and their serum uPA levels were measured before and after chemotherapy,the serum uPA levels of different types of patients were compared before and after chemotherapy.Result:The serum uPA level of patients with different pathological types,pathological stages,degree of differentiation and lymph node metastasis after chemotherapy were lower than those before chemotherapy,the differences were statistically significant (P<0.05).The serum uPA levels in patients with non-serous cancer,stage Ⅰ or Ⅱ,low in moderately differentiated,and no lymph node metastasis before and after chemotherapy were lower than those in patients with serous cancer,stage Ⅲ or Ⅳ,highly differentiated,and lymph node metastasis,the differences were statistically significant (P<0.05).Conclusion:After chemotherapy,the serum uPA level in patients with epithelial ovaries has decreased.The change of serum uPA level in patients with chemotherapy for epithelial ovarian cancer can provide a reliable basis for patient prognosis evaluation.
作者
饶峰
但汉卿
RAO Feng;DAN Hanqing(Chibi People’s Hospital,Chibi 437300,China;不详)
出处
《中外医学研究》
2020年第17期136-138,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
卵巢上皮性癌
化疗
血清尿激酶型纤溶酶原激活物
Epithelial ovarian cancer
Chemotherapy
Serum urokinase-type plasminogen activator
作者简介
通信作者:但汉卿。
